Not available outside of the UK & Ireland.

Application

Target protein enrichment and quantification from complex background by mass spectrometry.

Components

Streptavidin High Binding Capacity Coated Plate S2577-1EASOLu-Trypsin EMS0004-100UGMS Denaturation Solution EMS00010-10MLRapid Trypsin Digestion Buffer EMS0009-30MLTris Buffered Saline with TWEEN^® 20 (TBST)powder, pH 8.0 T9039Tris Buffered Saline (TBS) powder, pH 8.0 T6664EZ-Pierce^™ plate seal Z721581-1EASee datasheet for more information.

Features and Benefits

Entire workflow including digest completed in under 5 hours, such that samples are injection ready at the end of the work day 96-well plate format has potential for automation in a liquid-handling system Bead-free system circumvents messy clean-up and eliminates risk of column clogging Plate strips allow user to run as many or as few samples as desired

General description

The Streptavidin IA-MS Immunoaffinity Mass Spectrometry Kit is a 96-well platform enabling robust, high-throughput quantification of proteins in complex backgrounds by LC-MS/MS. Users provide their own biotinylated capture molecule and internal standard (available separately, internal standards may be SIL peptides or preferably full length SIL protein) and the kit contains all other components needed for in-well enrichment and rapid trypsin digestion of samples. The plate format consists of 8-well strips allowing for partial runs, and avoids the high cost and potential LC column blockage associated with bead-based enrichment formats. The entire workflow can be performed in under 5 hours, resulting in digests ready for injection with no SPE or other cleanup required.

Legal Information

TWEEN is a registered trademark of Croda International PLC

EZ-Pierce is a trademark of Excel Scientific, Inc.

Packaging

Box with foam insert containing kit components.

Storage and Stability

2 years when stored at 2-8 °C.Related Presentation Development of a Plate-based Immunoaffinity LC-MS/MS Workflow for Sensitive Quantitation of Free Infliximab and Adalimumab in Human Serum (Poster, PDF)